citalopram has been researched along with Chronic Hepatitis C in 18 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Depression occurred in 14 patients receiving placebo and in 5 patients receiving escitalopram (Pearson χ², P = ." | 9.19 | Effects of escitalopram prophylaxis during antiviral treatment for chronic hepatitis C in patients with a history of intravenous drug use and depression. ( Bezemer, G; de Knegt, RJ; Hansen, BE; Hotho, DM; Janssen, HL; Van Gool, AR; Veldt, BJ, 2014) |
| "To examine whether preemptive antidepressant treatment with escitalopram can decrease the incidence or severity of depression associated with pegylated IFN-α in HCV-infected patients without a history of psychiatric disorders." | 9.16 | Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. ( Baumert, TF; Berg, T; Buggisch, P; Discher, T; Effenberger, S; Friebe, A; Fromm, G; Heinz, A; Heinze, L; Knop, V; Lieb, K; Link, R; Neumann, K; Ockenga, J; Reimer, J; Rentrop, M; Sarkar, R; Schaefer, M; Schlaepfer, T; Spengler, U; Weidenbach, H; Zeuzem, S, 2012) |
| "Antidepressants are effective in treating interferon-α/ribavirin (IFN-α/RBV)-associated depression during or after treatment of chronic hepatitis C (CHC)." | 8.89 | Can antidepressants prevent pegylated interferon-α/ribavirin-associated depression in patients with chronic hepatitis C: meta-analysis of randomized, double-blind, placebo-controlled trials? ( Hou, XJ; Wang, J; Xu, JH; Yu, YY, 2013) |
| "To evaluate the risk factors of psychiatric adverse events associated with PEG interferon and ribavirin treatment for chronic hepatitis C and assess the efficacy of escitalopram intervention for these adverse effects." | 7.79 | [Escitalopram for intervention of psychiatric adverse events during peginterferon-alfa-2a and ribavirin treatment for chronic hepatitis C]. ( Pan, J; Qi, M; Su, M; Zhang, H; Zhou, B, 2013) |
| "All citalopram patients were able to complete interferon therapy as planned." | 6.73 | Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. ( Hofbauer, I; Keicher, C; Kraus, MR; Schäfer, A; Scheurlen, M; Schöttker, K; Weissbrich, B, 2008) |
| "Depression occurred in 14 patients receiving placebo and in 5 patients receiving escitalopram (Pearson χ², P = ." | 5.19 | Effects of escitalopram prophylaxis during antiviral treatment for chronic hepatitis C in patients with a history of intravenous drug use and depression. ( Bezemer, G; de Knegt, RJ; Hansen, BE; Hotho, DM; Janssen, HL; Van Gool, AR; Veldt, BJ, 2014) |
| "To examine whether preemptive antidepressant treatment with escitalopram can decrease the incidence or severity of depression associated with pegylated IFN-α in HCV-infected patients without a history of psychiatric disorders." | 5.16 | Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. ( Baumert, TF; Berg, T; Buggisch, P; Discher, T; Effenberger, S; Friebe, A; Fromm, G; Heinz, A; Heinze, L; Knop, V; Lieb, K; Link, R; Neumann, K; Ockenga, J; Reimer, J; Rentrop, M; Sarkar, R; Schaefer, M; Schlaepfer, T; Spengler, U; Weidenbach, H; Zeuzem, S, 2012) |
| "Antidepressants are effective in treating interferon-α/ribavirin (IFN-α/RBV)-associated depression during or after treatment of chronic hepatitis C (CHC)." | 4.89 | Can antidepressants prevent pegylated interferon-α/ribavirin-associated depression in patients with chronic hepatitis C: meta-analysis of randomized, double-blind, placebo-controlled trials? ( Hou, XJ; Wang, J; Xu, JH; Yu, YY, 2013) |
| "To evaluate the risk factors of psychiatric adverse events associated with PEG interferon and ribavirin treatment for chronic hepatitis C and assess the efficacy of escitalopram intervention for these adverse effects." | 3.79 | [Escitalopram for intervention of psychiatric adverse events during peginterferon-alfa-2a and ribavirin treatment for chronic hepatitis C]. ( Pan, J; Qi, M; Su, M; Zhang, H; Zhou, B, 2013) |
| " Patients also received prophylactic citalopram to minimize the risk of interferon-induced depression." | 3.76 | High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin. ( Ackermann, G; Waizmann, M, 2010) |
| "All citalopram patients were able to complete interferon therapy as planned." | 2.73 | Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. ( Hofbauer, I; Keicher, C; Kraus, MR; Schäfer, A; Scheurlen, M; Schöttker, K; Weissbrich, B, 2008) |
| "Depression was assessed using the Hospital Anxiety and Depression Scale (HADS)." | 1.36 | Platelet serotonin (5-HT) levels in interferon-treated patients with hepatitis C and its possible association with interferon-induced depression. ( Keicher, C; Kraus, MR; Rieger, P; Schäfer, A; Scheurlen, M; Seufert, J; Weissbrich, B, 2010) |
| "Depression is common in hepatitis C, exacerbated by interferon, and is a major reason for discontinuing interferon therapy." | 1.34 | Preventing relapse of major depression during interferon-alpha therapy for hepatitis C--A pilot study. ( Fucci, JC; Gleason, OC; Philipsen, MA; Yates, WR, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (33.33) | 29.6817 |
| 2010's | 12 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Qi, M | 1 |
| Zhou, B | 1 |
| Su, M | 1 |
| Pan, J | 1 |
| Zhang, H | 1 |
| Hou, XJ | 1 |
| Xu, JH | 1 |
| Wang, J | 1 |
| Yu, YY | 1 |
| Hotho, DM | 1 |
| Bezemer, G | 2 |
| Hansen, BE | 2 |
| Van Gool, AR | 2 |
| de Knegt, RJ | 2 |
| Janssen, HL | 2 |
| Veldt, BJ | 1 |
| Sockalingam, S | 1 |
| Sheehan, K | 1 |
| Feld, JJ | 1 |
| Shah, H | 1 |
| Montes, ML | 1 |
| Fraile, JM | 1 |
| González, JJ | 1 |
| Arribas, JR | 1 |
| Schäfer, A | 2 |
| Scheurlen, M | 2 |
| Seufert, J | 1 |
| Keicher, C | 2 |
| Weissbrich, B | 2 |
| Rieger, P | 1 |
| Kraus, MR | 2 |
| Waizmann, M | 1 |
| Ackermann, G | 1 |
| Wiwanitkit, V | 1 |
| Drenth, JP | 1 |
| Droogleever Fortuyn, HA | 1 |
| Weegink, CJ | 1 |
| Hengeveld, MW | 1 |
| Schaefer, M | 3 |
| Sarkar, R | 1 |
| Knop, V | 1 |
| Effenberger, S | 1 |
| Friebe, A | 1 |
| Heinze, L | 1 |
| Spengler, U | 1 |
| Schlaepfer, T | 1 |
| Reimer, J | 1 |
| Buggisch, P | 1 |
| Ockenga, J | 1 |
| Link, R | 1 |
| Rentrop, M | 1 |
| Weidenbach, H | 1 |
| Fromm, G | 1 |
| Lieb, K | 1 |
| Baumert, TF | 1 |
| Heinz, A | 2 |
| Discher, T | 1 |
| Neumann, K | 2 |
| Zeuzem, S | 1 |
| Berg, T | 3 |
| Landman, GW | 1 |
| Sarkar, S | 1 |
| Loftis, JM | 1 |
| Socherman, RE | 1 |
| Howell, CD | 1 |
| Whitehead, AJ | 1 |
| Hill, JA | 1 |
| Dominitz, JA | 1 |
| Hauser, P | 1 |
| Laguno, M | 1 |
| Blanch, J | 1 |
| Murillas, J | 1 |
| Blanco, JL | 1 |
| León, A | 1 |
| Lonca, M | 1 |
| Larrousse, M | 1 |
| Biglia, A | 1 |
| Martinez, E | 1 |
| García, F | 1 |
| Miró, JM | 1 |
| de Pablo, J | 1 |
| Gatell, JM | 1 |
| Mallolas, J | 1 |
| Schwaiger, M | 1 |
| Garkisch, AS | 1 |
| Pich, M | 1 |
| Hinzpeter, A | 1 |
| Uebelhack, R | 1 |
| van Boemmel, F | 1 |
| Gleason, OC | 1 |
| Fucci, JC | 1 |
| Yates, WR | 1 |
| Philipsen, MA | 1 |
| Schöttker, K | 1 |
| Hofbauer, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Frequency of Anxiety and Depression in Chronic Hepatitis C Patients Recieving Direct-Acting Antiviral Agents.[NCT03894696] | 200 participants (Anticipated) | Observational | 2019-08-01 | Not yet recruiting | |||
| Efficacy and Tolerability of Escitalopram for the Prevention of Pegylated Interferon Alfa Associated Depression in Patients With Chronic Hepatitis C Infection: a Randomized Controlled Trial.[NCT00136318] | Phase 3 | 208 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00136318)
Timeframe: major depression during 24 or 48 weeks of antiviral therapy
| Intervention | percentage of participants (Number) |
|---|---|
| Escitalopram | 8 |
| Placebo | 17 |
"Clinically relevant depression (MADRS score of 13 or higher) during antiviral treatment presented as percentage of participants with MADRS scores > 13 (entire time period: from starting study medication until end of antiviral treatment = 48 weeks in patients with genotype 1 or 4 and 24 weeks for patients with genotype 2 or 3)" (NCT00136318)
Timeframe: 50 weeks for genotypes 1 or 4 and 26 weeks for patients with genotype 2 or 3
| Intervention | percentage of participants (Number) |
|---|---|
| Escitalopram | 32 |
| Placebo | 59 |
Number of patients who did not develop at any time of antiviral treatment (up to 48 weeks) a MADRS score of 13 or more as a sign of clinically relevant depression (NCT00136318)
Timeframe: Patients free of depression during 24 or 48 weeks of antiviral therapy
| Intervention | participants (Number) |
|---|---|
| Escitalopram | 60 |
| Placebo | 40 |
(NCT00136318)
Timeframe: severe depression during 24 or 48 weeks of antiviral therapy
| Intervention | percentage of participants (Number) |
|---|---|
| Escitalopram | 1 |
| Placebo | 12 |
(negative Polymerase Chain Reaction (PCR) 6 months after the end of antiviral treatment) (NCT00136318)
Timeframe: assessed 24 weeks after end of antiviral treatment
| Intervention | percentage of participants (Number) |
|---|---|
| Escitalopram | 56 |
| Placebo | 46 |
1 review available for citalopram and Chronic Hepatitis C
| Article | Year |
|---|---|
Can antidepressants prevent pegylated interferon-α/ribavirin-associated depression in patients with chronic hepatitis C: meta-analysis of randomized, double-blind, placebo-controlled trials?
Topics: Antidepressive Agents; Antiviral Agents; Citalopram; Depression; Double-Blind Method; Hepatitis C, C | 2013 |
6 trials available for citalopram and Chronic Hepatitis C
| Article | Year |
|---|---|
Effects of escitalopram prophylaxis during antiviral treatment for chronic hepatitis C in patients with a history of intravenous drug use and depression.
Topics: Aged; Antiviral Agents; Citalopram; Comorbidity; Depression; Female; Hepatitis C, Chronic; Humans; I | 2014 |
Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Anxiety Disorders; Citalopram; Double-Blind Method; Drug Therapy, Combinati | 2011 |
Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antiviral Agents; Citalopram; Depression; Dep | 2012 |
Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C.
Topics: Adult; Antiviral Agents; Citalopram; Depressive Disorder, Major; Drug Therapy, Combination; Female; | 2004 |
Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C.
Topics: Adult; Antidepressive Agents, Second-Generation; Antiviral Agents; Citalopram; Depressive Disorder, | 2005 |
Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study.
Topics: Adult; Antidepressive Agents, Second-Generation; Antiviral Agents; Citalopram; Depressive Disorder; | 2008 |
11 other studies available for citalopram and Chronic Hepatitis C
| Article | Year |
|---|---|
[Escitalopram for intervention of psychiatric adverse events during peginterferon-alfa-2a and ribavirin treatment for chronic hepatitis C].
Topics: Adult; Antidepressive Agents, Second-Generation; Antiviral Agents; Citalopram; Depression; Female; H | 2013 |
Psychiatric care during hepatitis C treatment: the changing role of psychiatrists in the era of direct-acting antivirals.
Topics: Antidepressive Agents; Antiviral Agents; Citalopram; Comorbidity; Cooperative Behavior; Delirium; De | 2015 |
[Chorea during treatment with pegylated interferon and ribavirin in HIV-HCV coinfected patient].
Topics: Adult; Anti-HIV Agents; Antidepressive Agents; Antiviral Agents; Anxiety Disorders; Chorea; Citalopr | 2009 |
Platelet serotonin (5-HT) levels in interferon-treated patients with hepatitis C and its possible association with interferon-induced depression.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; Blood Platelets; Citalopram; Depression; Drug | 2010 |
High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin.
Topics: Adult; Antidepressive Agents; Antiviral Agents; Buprenorphine; Citalopram; Depression; Directly Obse | 2010 |
Antidepressant pretreatment and symptomatic treatment in interferon treatment.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; Hepatitis C, Chron | 2010 |
Summaries for Patients. Prevention of depression in patients treated for chronic hepatitis C virus infection with interferon-alpha.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antiviral Agents; Citalopram; Depression; Dou | 2012 |
Escitalopram for the prevention of peginterferon-α2a-associated depression.
Topics: Antidepressive Agents, Second-Generation; Antiviral Agents; Citalopram; Depression; Female; Hepatiti | 2013 |
Escitalopram for the prevention of peginterferon-α2a-associated depression.
Topics: Antidepressive Agents, Second-Generation; Antiviral Agents; Citalopram; Depression; Female; Hepatiti | 2013 |
Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis C.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Depression; Drug Therapy, Combination; | 2004 |
Preventing relapse of major depression during interferon-alpha therapy for hepatitis C--A pilot study.
Topics: Adolescent; Adult; Antidepressive Agents; Antiviral Agents; Citalopram; Depression; Drug Therapy, Co | 2007 |